He is just the latest to make this claim and is joining a growing number of Americans who’ve filed a lawsuit against the Japanese manufacturer of the drug, Takeda Pharmaceuticals and its subsidiary companies, and its American marketing partner, Eli Lilly.

The man is being represented by the national law firm of Parker Waichman LLP, which represents other victims of Actos-related bladder cancer. Jerrold S. Parker, a founding partner with the firm, has been named to the Plaintiff’s Steering Committee as part of Multidistrict Litigation in U.S. District Court for the Western District of Louisiana. This latest lawsuit has been added to that MDL.

According to a release from the firm announcing the lawsuit, the Louisiana man took Actos to regulate blood sugar levels as part of his treatment for type 2 diabetes. He was prescribed the drug from 2006 until 2008 when he eventually developed bladder cancer. His lawsuit, like others filed as part of the MDL, claims he was not warned about the potential risk of bladder cancer caused by Actos.

It was not until 2010 that the Food and Drug Administration warned that taking Actos at high doses or for longer than a year can result in bladder cancer.

The lawsuit seeks damages for “severe mental and physical pain and suffering, past and future permanent injuries and emotional distress, economic loss due to medical expenses and living related expenses as a result of a new lifestyle,” according to the release.